Whats new

Whats new.

CLSA - Efti & Keytruda’s excellent adventure; OS data shows meaningful benefit in NSCLC, without need for chemo (Analyst: Andrew Paine)

May 17th 2023

For a copy of this analyst report please contact your CLSA advisor

Go back